Who are Ortho Evra's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Natazia, Faslodex, Elocon, Gynorest, Progesterone, Aygestin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/norelgestromin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Ortho Evra — Competitive Intelligence Brief

Ortho Evra (NORELGESTROMIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Estrogen [EPC]. Area: Metabolic.

marketed Estrogen [EPC] Progesterone receptor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Ortho Evra (NORELGESTROMIN). Ortho Evra works by binding to the progesterone receptor in the body, mimicking the effects of the natural hormone progesterone.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ortho Evra TARGET	NORELGESTROMIN		marketed	Estrogen [EPC]	Progesterone receptor	2001-01-01
Natazia	DIENOGEST	Mochida Pharmaceutical Co., Ltd.	marketed	Progestin	Progesterone receptor	2010-01-01
Faslodex	fulvestrant	AstraZeneca	marketed	Estrogen Receptor Antagonist [EPC]	Progesterone receptor	2002-01-01
Elocon	MOMETASONE FUROATE	Merck & Co.	marketed	Corticosteroid	Progesterone receptor	1987-01-01
Gynorest	DYDROGESTERONE	Solvay	marketed	dydrogesterone	Progesterone receptor	1982-01-01
Progesterone	Progesterone plus HCG	Dunamenti REK Istenhegyi IVF Center	marketed	Progesterone [EPC]	progesterone receptor, luteinizing hormone/choriogonadotropin receptor	1978-01-01
Aygestin	NORETHINDRONE ACETATE	Duramed Res	marketed	Estrogen [EPC]	Progesterone receptor	1973-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-11-29 — Elocon · 7544192 · Method of Use · US
2027-06-12 — Elocon · 8025635 · Formulation · US
2028-01-30 — Natazia · 8153616 · US
2031-10-03 — Elocon · 10357640 · Method of Use · US
2032-02-08 — Elocon · 8763222 · Formulation · US
2034-02-14 — Faslodex · 10188663 · Formulation · US
2034-02-14 — Faslodex · 9833459 · Formulation · US
2034-03-13 — Elocon · 10406332 · Formulation · US
2034-05-17 — Faslodex · 9271990 · Formulation · US
2034-11-24 — Elocon · 10232152 · Formulation · US

Sponsor landscape (Estrogen [EPC] class)

· 4 drugs in this class
Pfizer · 2 drugs in this class
Mayne Pharma · 1 drug in this class
University of Colorado, Denver · 1 drug in this class
Wyeth Pharms Pfizer · 1 drug in this class
Oregon Health and Science University · 1 drug in this class
Duramed Res · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ortho Evra — Competitive Intelligence Brief. https://druglandscape.com/ci/norelgestromin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab